Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kyntra Bio (KYNB), Crispr Therapeutics AG (CRSP) and GoodRx Holdings (GDRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kyntra Bio (KYNB – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and GoodRx Holdings (GDRX – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kyntra Bio (KYNB)
H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Kyntra Bio on February 27 and set a price target of $43.00. The company’s shares closed last Friday at $6.93.
According to TipRanks.com, Keller has 0 stars on 0-5 stars ranking scale with an average return of
Kyntra Bio has an analyst consensus of Moderate Buy, with a price target consensus of $43.00.
See the top stocks recommended by analysts >>
Crispr Therapeutics AG (CRSP)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG. The company’s shares closed last Friday at $60.14.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $70.21.
GoodRx Holdings (GDRX)
Truist Financial analyst Jailendra Singh maintained a Hold rating on GoodRx Holdings today. The company’s shares closed last Friday at $1.87.
According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of
GoodRx Holdings has an analyst consensus of Hold, with a price target consensus of $3.24, which is a 62.8% upside from current levels. In a report issued on February 26, J.P. Morgan also downgraded the stock to Hold.
